Survival analyses from the ZEBRA study: goserelin (Zoladex™) versus CMF in premenopausal women with node-positive breast cancer

The <f><unl type="bar" STYLE="S">Z</unl></f>oladex <f><unl type="bar" STYLE="S">E</unl></f>arly <f><unl type="bar" STYLE="S">B</unl></f>reast Cancer <f><unl type="bar" STYLE="S">R</unl></f>esearch <f><unl type="bar" STYLE="S">A</unl></f>ssociation (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex™) with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy in pre-/perimenopausal women with node-positive early breast cancer. The results of disease-free survival (DFS) analyses have already been published. Here we present an update including data on overall survival (OS) from the ZEBRA trial at a median follow-up of 7.3 years. In patients with oestrogen receptor (ER)-positive tumours, non-inferiority of goserelin versus CMF for OS was shown; goserelin was again shown to be equivalent to CMF for DFS. This updated analysis has demonstrated that the two treatments are also equivalent for distant disease-free survival (DDFS). In patients with ER-negative disease, goserelin was inferior to CMF for DFS, DDFS and OS. This follow-up analysis confirms the previously reported outcomes from the ZEBRA trial and demonstrates that goserelin offers an effective alternative to CMF chemotherapy for adjuvant therapy of premenopausal patients with ER-positive, node-positive early breast cancer. [Copyright &y& Elsevier]